The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis
Open accessAbstract
BACKGROUND: Maintenance of remission is a major issue in inflammatory bowel disease. In ulcerative colitis, the evidence for the effectiveness of azathioprine and 6-mercaptopurine for the maintenance of remission is still controversial. OBJECTIVES: To assess the effectiveness and safety of azathioprine and 6-mercaptopurine for maintaining remission of ulcerative colitis. SEARCH METHODS: The MEDLINE, EMBASE and Cochrane Library databases were searched from inception to 30 July 2015. Both full randomized controlled trials and associated abstracts were included. SELECTION CRITERIA: Randomized controlled trials of at least 12 months duration that compared azathioprine or 6-mercaptopurine with placebo or standard maintenance therapy (e.g. mesalazine) were included. DATA COLLECTION AND ANALYSIS: Two authors independently extracted data using standard forms. Disagreements were solved by consensus including a third author. Study quality was assessed using the Cochrane risk of bias tool. The primary outcome was failure to maintain clinical or endoscopic remission. Secondary outcomes included adverse events and withdrawal due to adverse events. Analyses were performed separately by type of control (placebo, or active comparator). Pooled risk ratios were calculated based on the fixed-effect model unless heterogeneity was shown. The GRADE approach was used to assess the overall quality of evidence for pooled outcomes. MAIN RESULTS: Seven studies including 302 patients with ulcerative colitis were included in the review. The risk of bias was high in three of the studies due to lack of blinding. Azathioprine was shown to be significantly superior to placebo for maintenance of remission. Fourty-four per cent (51/115) of azathioprine patients failed to maintain remission compared to 65% (76/117) of placebo patients (4 studies, 232 patients; RR 0.68, 95% CI 0.54 to 0.86). A GRADE analysis rated the overall quality of the evidence for this outcome as low due to risk of bias and imprecision (sparse data). Two trials that compared 6-mercaptopurine to mesalazine, or azathioprine to sulfasalazine showed significant heterogeneity and thus were not pooled. Fifty per cent (7/14) of 6-mercaptopurine patients failed to maintain remission compared to 100% (8/8) of mesalazine patients (1 study, 22 patients; RR 0.53, 95% CI 0.31 to 0.90). Fifty-eight per cent (7/12) of azathioprine patients failed to maintain remission compared to 38% (5/13) of sulfasalazine patients (1 study, 25 patients; RR 1.52, 95% CI 0.66 to 3.50). One small study found that 6-mercaptopurine was superior to methotrexate for maintenance of remission. In the study, 50% (7/14) of 6-mercaptopurine patients and 92% (11/12) of methotrexate patients failed to maintain remission (1 study, 26 patients; RR 0.55, 95% CI 0.31 to 0.95). One very small study compared azathioprine with cyclosporin and found that there was no significant difference between patients failing remission on azathioprine (50%, 4/8) or cyclosporin (62.5%, 5/8) (1 study, 16 patients, RR 0.80 95% CI 0.33 to 1.92). When placebo-controlled studies were pooled with aminosalicylate-comparator studies to assess adverse events, there was no statistically significant difference between azathioprine and control in the incidence of adverse events. Nine per cent (11/127) of azathioprine patients experienced at least one adverse event compared to 2% (3/130) of placebo patients (5 studies, 257 patients; RR 2.82, 95% CI 0.99 to 8.01). Patients receiving azathioprine were at significantly increased risk of withdrawing due to adverse events. Eight per cent (8/101) of azathioprine patients withdrew due to adverse events compared to 0% (0/98) of control patients (5 studies, 199 patients; RR 5.43, 95% CI 1.02 to 28.75). Adverse events related to study medication included acute pancreatitis (3 cases, plus 1 case on cyclosporin) and significant bone marrow suppression (5 cases). Deaths, opportunistic infection or neoplasia were not reported. AUTHORS' CONCLUSIONS: Azathioprine therapy appears to be more effective than placebo for maintenance of remission in ulcerative colitis. Azathioprine or 6-mercaptopurine may be effective as maintenance therapy for patients who have failed or cannot tolerate mesalazine or sulfasalazine and for patients who require repeated courses of steroids. More research is needed to evaluate superiority over standard maintenance therapy, especially in the light of a potential for adverse events from azathioprine. This review updates the existing review of azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis which was published in the Cochrane Library (September 2012).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
Pharmacological interventions for somatoform disorders in adults
Kleinstäuber, M., Witthöft, M., Steffanowski, A., van Marwijk, H., Hiller, W., & Lambert, M. J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010628.pub2 · Cited by 11,335
Schulz (1995) · doi:10.1001/jama.1995.03520290060030 · Cited by 5,634
(2008) · Cited by 3,790
Weinshilboum, R. M., & Sladek, S. L. (1980) · PubMed · Cited by 1,195
Published by John Wiley & Sons Ltd
Modarresi, O. A. F., & Shakibaie, M. M. M. R. (2015) · Cited by 1,111
Chapter 12: Interpreting results and drawing conclusions
Schünemann, H. J., Oxman, A. D., Jonathan, J., & Glasziou, P. (2011) · Cited by 870
Kandiel, A., Fraser, A. G., Korelitz, B. I., Brensinger, C., & Lewis, J. D. (2005) · Gut · doi:10.1136/gut.2004.049460 · Cited by 808
Colombel, J., Ferrari, N., Debuysere, H., Marteau, P., Gendre, J., Bonaz, B., Soulé, J.-C., Modigliani, R., Touze, Y., Catala, P., et al. (2000) · Gastroenterology · doi:10.1016/s0016-5085(00)70354-4 · Cited by 619
Variation Between Observers in Describing Mucosal Appearances in Proctocolitis
Baron, J. H., Connell, A. M., & Lennard-Jones, J. E. (1964) · BMJ · doi:10.1136/bmj.1.5375.89 · Cited by 611
Risk of Melanoma and Nonmelanoma Skin Cancer Among Patients With Inflammatory Bowel Disease
Long, M. D., Martin, C. F., Pipkin, C. A., Herfarth, H. H., Sandler, R. S., & Kappelman, M. D. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.05.004 · Cited by 526
Ardizzone, S., Maconi, G., Russo, A., Imbesi, V, Colombo, E., & Bianchi Porro, G. (2006) · Gut · doi:10.1136/gut.2005.068809 · Cited by 505
Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis
Wang, Y., Parker, C. E., Feagan, B. G., & MacDonald, J. K. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000544.pub4 · Cited by 483
Self-citationRandomised controlled trial of azathioprine withdrawal in ulcerative colitis.
Hawthorne, A. B., Logan, R. F., Hawkey, C. J., Foster, P. N., Axon, A. T., Swarbrick, E. T., Scott, B. B., & Lennard-Jones, J. E. (1992) · BMJ · doi:10.1136/bmj.305.6844.20 · Cited by 452
Kotlyar, D. S., Lewis, J. D., Beaugerie, L., Tierney, A., Brensinger, C. M., Gisbert, J. P., Loftus, E. V., Peyrin-Biroulet, L., Blonski, W. C., Van Domselaar, M., et al. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.05.015 · Cited by 414
Bressler, B., Marshall, J. K., Bernstein, C. N., Bitton, A., Jones, J., Leontiadis, G. I., Panaccione, R., Steinhart, A. H., Tse, F., Feagan, B., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.03.001 · Cited by 413
Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease
Chande, N., Patton, P. H., Tsoulis, D. J., Thomas, B. S., & MacDonald, J. K. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000067.pub3 · Cited by 402
Self-citationLichtenstein, G. R., Sbreu, M. T., Cohen, R. D., & Tremaine, W. J. (2006) · PubMed · Cited by 371
Azathioprine in Ulcerative Colitis: Final Report on Controlled Therapeutic Trial
Jewell, D. P., & Truelove, S. C. (1974) · BMJ · doi:10.1136/bmj.4.5945.627 · Cited by 332
Francella, A., Dyan, A., Bodian, C., Rubin, P., Chapman, M., & Present, D. H. (2003) · Gastroenterology · doi:10.1053/gast.2003.50014 · Cited by 331
Azathioprine for maintenance of remission in Crohn's disease
Pearson, D., May, G., Fick, G., & Sutherland, L. (1998) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000067 · Cited by 304
Cohen, R. D., Woseth, D. M., Thisted, R. A., & Hanauer, S. B. (2000) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2000.01940.x · Cited by 277
Azathioprine, 6-mercaptopurine in inflammatory bowel disease: Pharmacology, efficacy, and safety
Dubinsky, M. C. (2004) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(04)00344-1 · Cited by 249
Azathioprine for maintenance of remission in Crohn's disease: Benefits outweigh the risk of lymphoma
Lewis, J. D., Schwartz, J. S., & Lichtenstein, G. R. (2000) · Gastroenterology · doi:10.1016/s0016-5085(00)70353-2 · Cited by 242
GEARRY, R. B., & BARCLAY, M. L. (2005) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2005.03832.x · Cited by 236
Controlled trial of azathioprine in chronic ulcerative colitis.
Kirk, A. P., & Lennard-Jones, J. E. (1982) · BMJ · doi:10.1136/bmj.284.6325.1291 · Cited by 228
Maté-Jiménez, J., Hermida, C., Cantero-Perona, J., & Moreno-Otero, R. (2000) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200012110-00010 · Cited by 227
A Controlled Trial of Azathioprine in the Management of Chronic Ulcerative Colitis
Rosenberg, J. L., Wall, A. J., Levin, B., Binder, H. J., & Kirsner, J. B. (1975) · Gastroenterology · doi:10.1016/s0016-5085(19)32641-1 · Cited by 224
Rectal aminosalicylate therapy for distal ulcerative colitis: a meta‐analysis
MARSHALL, J. K., & IRVINE, E. J. (1995) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.1995.tb00384.x · Cited by 194
Chouchana, L., Narjoz, C., Beaune, P., Loriot, M. ‐., & Roblin, X. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04905.x · Cited by 164
Gearry, R. B., Barclay, M. L., Burt, M. J., Collett, J. A., & Chapman, B. A. (2004) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.926 · Cited by 159
Cuffari, C., Dassopoulos, T., Turnbough, L., Thompson, R. E., & Bayless, T. M. (2004) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(04)00127-2 · Cited by 156
Fernández‐Bañares, F., Bertrán, X., Esteve, M., Cabré, E., Menacho, M., Humbert, P., Planas, R., & Gassull, M. A. (1996) · PubMed · Cited by 154
Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis
Timmer, A., McDonald, J. W., & MacDonald, J. K. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000478.pub2 · Cited by 153
Self-citationAzathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis
Timmer, A., McDonald, J. W., Tsoulis, D. J., et al. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000478.pub3 · Cited by 126
Self-citationCassinotti, A., Actis, G. C., Duca, P., Massari, A., Colombo, E. M., Gai, E., Annese, V., D'Albasio, G., Manes, G., Travis, S. P. L., et al. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.410 · Cited by 125
Hibi∥, T., Naganuma, M., Kitahora, T., Kinjyo, F., & Shimoyama, T. (2003) · Journal of Gastroenterology · doi:10.1007/s00535-003-1139-2 · Cited by 124
Azathioprine in Steroid-Resistant and Steroid-Dependent Ulcerative Colitis
Ardizzone, S., Molteni, F., Imbesi, V., Bollani, S., & Porro, G. B. (1997) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-199707000-00007 · Cited by 111
The beneficial effect of azathioprine on maintenance of remission in severe ulcerative colitis
Sood, A., Kaushal, V., Midha, V., Bhatia, K. L., Sood, N., & Malhotra, V. (2002) · Journal of Gastroenterology · doi:10.1007/s005350200034 · Cited by 109
Domènech, E., García-Planella, E., Bernal, I., Rosinach, M., Cabré, E., Fluvià, L., Boix, J., & Gassull, M. À. (2002) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2002.01385.x · Cited by 87
Holtmann, M. H., Krummenauer, F., Claas, C., Kremeyer, K., Lorenz, D., Rainer, O., Vogel, I., Böcker, U., Böhm, S. K., Büning, C., et al. (2006) · Digestive Diseases and Sciences · doi:10.1007/s10620-005-9037-5 · Cited by 84
Rectal 5-aminosalicylic acid for maintenance of remission in ulcerative colitis
Marshall, J. K., Thabane, M. E., Steinhart, A. H., Newman, J. R., Anand, A., & Irvine, E. J. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004118.pub2 · Cited by 79
Aithal, G. P., & Mansfield, J. C. (2001) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2001.01023.x · Cited by 72
Treatment of inflammatory bowel disease with azathioprine and 6-mercaptopurine
Su, C. G., & Lichtenstein, G. R. (2004) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2004.02.004 · Cited by 63
Azathioprine versus sulfasalazine in maintenance of remission in severe ulcerative colitis.
Sood, A., Midha, V., Sood, N., & Avasthi, G. (2003) · PubMed · Cited by 59
A national survey on the patterns of treatment of inflammatory bowel disease in Canada
Hilsden, R. J., Verhoef, M. J., Best, A., & Pocobelli, G. S. (2003) · BMC Gastroenterology · doi:10.1186/1471-230x-3-10 · Cited by 39
Floch, M. H. (2004) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-200408000-00020 · Cited by 19
Tolerability of Aminosalicylates in Inflammatory Bowel Disease
Ishaq, S., & Green, J. R. (2001) · BioDrugs · doi:10.2165/00063030-200115050-00005 · Cited by 14
Medical Management of Ulcerative Colitis with a Specific Focus on 5-Aminosalicylates
Freeman, H. J. (2012) · Clinical Medicine Insights Gastroenterology · doi:10.4137/cgast.s8673 · Cited by 11
8 Safety of corticosteroids and immunosuppressive agents in ulcerative colitis
Connell, W. R., & Taylor, A. C. F. (1997) · Baillière s Clinical Gastroenterology · doi:10.1016/s0950-3528(97)90057-9 · Cited by 4
Cited by
Lamb, C. A., Kennedy, N. A., Raine, T., Hendy, P. A., Smith, P. J., Limdi, J. K., Hayee, B., Lomer, M. C. E., Parkes, G. C., Selinger, C., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-318484 · Cited by 2,346
Dignass, A., Lindsay, J. O., Sturm, A., Windsor, A., Colombel, J.-F., Allez, M., D'Haens, G., D'Hoore, A., Mantzaris, G., Novacek, G., et al. (2012) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2012.09.002 · Cited by 1,548
Guidelines for the management of inflammatory bowel disease in adults
Mowat, C., Cole, A., Windsor, A., Ahmad, T., Arnott, I., Driscoll, R., Mitton, S., Orchard, T., Rutter, M., Younge, L., et al. (2011) · Gut · doi:10.1136/gut.2010.224154 · Cited by 1,419
Undue reliance on I 2 in assessing heterogeneity may mislead
Rücker, G., Schwarzer, G., Carpenter, J. R., & Schumacher, M. (2008) · BMC Medical Research Methodology · doi:10.1186/1471-2288-8-79 · Cited by 1,287
Harbord, M., Eliakim, R., Bettenworth, D., Karmiris, K., Katsanos, K., Kopylov, U., Kucharzik, T., Molnár, T., Raine, T., Sebastian, S., et al. (2017) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjx009 · Cited by 1,180
Metadata
- Authors
- Timmer, A., Patton, P. H., Chande, N., McDonald, J. W., & MacDonald, J. K.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2016-05-18
- Volume
- 2016
- Issue
- 5
- Pages
- CD000478-CD000478
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W1499566049
- Cited by
- 528
- References
- 52
- FWCI
- 35.47
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.